
MSI TESTING MOLECULAR PCR VERSUS TRADITIONAL IHC TESTING





TRADITIONAL IHC TESTING VERSUS MOLECULAR PCR TESTING



MSI by PCR and deficient MMR by IHC provide fundamentally different information about tumor samples.

Immunohistochemistry (IHC) measures the presence or absence of Mismatch Repair (MMR) proteins; however, the presence of MMR protein expression is not necessarily a conclusive measure of MMR function. There can be a loss in function of these proteins without a corresponding loss of the protein in the cell, with 5-10% of proteins retaining antigenicity when they are not functional.¹

Microsatelite Instability (MSI) by PCR directly measures changes in DNA caused by loss of MMR protein function as opposed to assessing the proteins themselves in IHC.

This makes MSI a functional measure of mismatch repair deficiency that detects loss in MMR repair function, regardless of the cause.¹

MSI TESTING IS RECOMMENDED FOR VARIOUS APPLICATIONS

MSI TESTING FOR LYNCH SCREENING

In international guidelines **both MMR by IHC and/or MSI by PCR are recommended** methods for Lynch screening.²

The **decision** about which screening method to be used depends primarily on the **availability of resources** and **expertise of the lab.**

ESMO RECOMMENDATION FOR CO-TESTING IN METASTATIC COLORECTAL CANCER FOR IMMUNOTHERAPY INDICATION

ESMO recommends to combine both tests to assess the eligibility to treatment with immune checkpoint inhibitors of mCRC and other cancers of the Lynch syndrome spectrum.^{3,4}

IHC LACKS STANDARDIZATION WITH POTENTIAL IMPACT ON PERFORMANCE

CURRENT IHC CHALLENGES - RESULT REPORTING

- Subjective interpretation
- Molecular confirmation needed for doubtful cases
- No consensus criteria on staining cut-off⁵
- Missense mutations in MMR genes leading to false negative result interpretation

CURRENT IHC CHALLENGES - WORKFLOW

• Wide variability of antibodies⁶

Proportion of sufficient results for MSH6 in NordiQC runs performed

	Run 32 2011	Run 43 2015	Run 52 2018
Participants, n=	90	153	242
Sufficient results	33%	63%	52%

- The recommendation to use 4 MMR antibodies is not yet widely adopted
- Wide variation in protocol parameters (e.g. dilution and incubation times)

IDYLLA™ MSI TEST ENSURES OPTIMAL DIAGNOSTIC RESULTS

Standardized, fully automated Idylla™ MSI testing overcomes the barriers of traditional PCR and IHC testing.

Features/Benefits	IHC	Traditional PCR	ldylla™ MSI
Identification of defective protein	1	-	-
Consequence of inactivation	-	 Image: A second s	√
Results within 2,5 hours	1	-	✓
Limited hands-on time	-	-	1
No batching needed	1	-	✓
MSI testing in any laboratory setting	1	-	✓
Standardized	-	-	✓
CE IVD from tissue to result	-	-	✓
Moving towards IVDR compliance	-	-	✓
Only 1 FFPE tissue section needed	-	-	✓
No need for paired normal tissue sample	-	-	✓
Fully automated sample-to-result	-	-	1
Contamination control	-	-	✓
Objective result interpretation	-	-	✓



REFERENCES

- (1) Funkhouser, W.K. Jr. et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J. Mol. Diagnostics 14, 91-103, 2012.
- (2) Stjepanovic et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 0:1-14, 2019.
- (3) Luchini et al. Esmo recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Annals of Oncology 30(8):1232-1243, 2019.
- (4) Cohen et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol. 5(4):551-555, 2019.
- (5) Sucha Sudarsanam et al. AMP Poster 2018.
- (6) NordiQC Assessment Run 52 2018 Mismatch repair protein MSH6: https://www.nordigc.org/downloads/ assessments/101 83.pdf

Biocartis NV Generaal de Wittelaan 11B 2800 Mechelen - Belaium +32 15 632 888 www.biocartis.com customerservice@biocartis.com

Follow us on **f**



Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and the Idylla trademarks and logos are used trademarks owned by Biocartis. Idylla™ platform is a CE-marked IVD in Europe. The Idylla™ MSI Test is a CE-marked IVD in Europe and validated for detection of MSI status in colorectal cancer. The Idylla™ MSI Test has not been validated for screening for Lynch or for use as CDx. Idylla™ is available for sale in EU, USA and some other countries. Please check availability with the local Biocartis sales representative. © Biocartis, December 2020





Distributed by Abacus dx 1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com